Concepedia

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

Stanley Roberts, Paul A. Andrews, Diann Blanset, Kelly M. Flagella, Boris Gorovits, Carmel M. Lynch, Pauline L. Martin, Kimberly Kramer-Stickland, Stéphane Thibault, Garvin L. Warner

Regulatory Toxicology and Pharmacology · 2013 · 43 citations · 38 references

DOI

Concepts

References

38

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.6K citations

, , +12

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

Ben‐Quan Shen, Keyang Xu, Luna Liu et al. · Nature Biotechnology · 2012 · 977 citations

, , +8

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Peter D. Senter, Eric L. Sievers · Nature Biotechnology · 2012 · 736 citations

, , +8

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Gregory P. Adams, Robert Schier, Adrian M. McCall et al. · PubMed · 2001 · 624 citations

, , +13

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

Anthony R. Mire‐Sluis, Yu Chen Barrett, Viswanath Devanarayan et al. · Journal of Immunological Methods · 2004 · 609 citations

, , +9